Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03894878 · ClinicalTrials.gov registry record
Association Between Genetic Variant Scores and Warfarin Effect
A clinical trial, sponsored by Cipherome.
- Completed
- Registry status
- 200
- Enrollment target
NCT03894878 is a clinical trial that has completed, run by Cipherome. The registered enrollment target is 200 participants.
The verdict
NCT03894878 has completed, sponsored by Cipherome.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, bleeding event, ischemic stroke, death) in participants taking warfarin for atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism (PE), and/or intracardiac thrombosis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-02-11 |
| Est. Completion | 2022-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03894878
The ClinicalTrials.gov registry entry for NCT03894878 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cipherome, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03894878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03894878 about?
NCT03894878 is a clinical study titled "Association Between Genetic Variant Scores and Warfarin Effect". Study objective is to determine whether there is an association between genetic variant risk scores and clinical outcomes (percent time in therapeutic range, time to reach therapeutic international normalized ratio (INR), INR ≥ 4, bleeding event, ischemic stroke, death) in participants taking warfar...
What is the current status of trial NCT03894878?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2019-02-11. Estimated completion is 2022-09-30.
Who is sponsoring clinical trial NCT03894878?
This trial is sponsored by Cipherome, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.